ALA—Photodynamic treatment in Lichen sclerosus—clinical and immunological outcome focusing on the assesment of antinuclear antibodies

Publication date: June 2017
Source:Photodiagnosis and Photodynamic Therapy, Volume 18
Author(s): Anita Olejek, Iwona Gabriel, Anna Bilska-Janosik, Iwona Kozak-Darmas, Aleksandra Kawczyk-Krupka
BackgroundLichen sclerosus (LS) is a difficult to treat, often relapsing disease with unknown background. Autoimmune diseases also coexist with LS. Over recent years photodynamic therapy (PDT) has been shown to be a noninvasive and successful therapeutic approach for the effective treatment of many conditions. However, the change of immune status of the patients based on ANA antibodies has not been yet reported. Our aim was to observe the clinical response followed by possible changes in autoimmune antibodies levels before and after PDT for LS.Material and MethodsWe enrolled 100 women with Lichen sclerosus with or without a concomitant autoimmune disease. All patients received 10 cycles of PDT (65 treated with DIOMED Light, 35 with PhotoDYN Light). We assessed autoimmune antibodies before and after PDT in addition to the clinical response evaluation.Two-year prospective controlled before-and-after study.ResultsFollowing PDT, patients showed a significant attenuation in symptoms' intensity (itching, pruritus, vulvar discomfort). After therapy 41% of patients had partial response, 51% of patients had no symptoms and 8% had persistent or worsened symptoms. The most frequent autoimmune disease were thyroid disorders, followed by vitiligo and arthritis. 57% patients with an additional autoimmune disease before PDT had ANA antibodies. The mean level of ANA in this group diminished significantly after PDT treatment (261.74 IU/ml before vs. 123.20 IU/ml after treatment).ConclusionBased on our results, we assume that PDT may influence the immune status of patients with Lichen sclerosus.



http://ift.tt/2n1E1vx